Learn more Got it! Making any protein possible ENGINEERING FIT-FOR-PURPOSE BIOTHERAPEUTICS Rooted in protein modeling and structure-guided engineering, our platforms make any protein possible, from cytotoxic anti-tumor biologics to antibody drug conjugates and immuno-oncology therapies. Building better biologicsTM RATIONALLY DESIGNED. ELEGANTLY SIMPLE. Fully integrated protein engineering technologies that make any protein possible. EXPLORE PLATFORMS AZYMETRIC™ Build the Best Bispecifics by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases ZYMELINK™ Enhance Therapeutic Response with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. EFECT™ Customize & Optimize Immune Response using precise antibody Fc modifications that tailor the antibody-mediated immune response Get the optimal response. Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control Technology’s (EFECT™) library of Fc region modifications. The EFECT™ library includes proprietary mutations to the CH2 domain of the antibody's Fc region to selectively modulate an antibody’s interactions with the Fc-gamma receptors (FcgR) expressed on the surface of immune cells and with a component of the complement pathway (i.e. C1q). HOW WE DIFFER Tailor therapeutic response by directing the activity of recruited immune cells. The EFECT™ platform creates antibody modifications that can: Up-regulate activity to enhance immune function Enhance antibody-dependent cellular cytotoxicity (ADCC; NK-cell driven) and antibody-dependent cellular phagocytosis (ADCP; macrophage driven) with EFECT antibody variants that selectively increase binding to the FcgRIIIa and/or FcgRIIa receptors Down-regulate activity to suppress auto-immunity Inhibit unwanted antibody-mediated auto-immunity by reducing immune responses of B cells with EFECT antibody variants that selectively increase binding to the FcgRIIb receptors Eliminate cytotoxicity Remove binding to all FcgRs and C1q where effector cell-mediated cytotoxicity is undesirable for therapeutic antibodies. PROTECT™ Tumor‑Specific Immune Co‑stimulation in a single, transferable, conditionally active design TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn